Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Vaccine improves survival in people with Acute Myeloid Leukemia (AML)

    November 20, 2026

    Neuroimplants: Autonomy Under Algorithmic Control

    November 20, 2026

    Three Sri Lankan startups selected for Uber Springboard 2026 Programme

    November 20, 2026
    Facebook X (Twitter) LinkedIn
    Trending
    • Vaccine improves survival in people with Acute Myeloid Leukemia (AML)
    • Neuroimplants: Autonomy Under Algorithmic Control
    • Three Sri Lankan startups selected for Uber Springboard 2026 Programme
    • Taking Sri Lankan technology to the global stage
    • AI is not about chasing the latest technology: MEDCUBE USA General Manager Kennedy J. Michael
    • Kaspersky: Binance and Polymarket hacks
    • Kaspersky: “dead” Retadup worm tried to infect at least 15,000 devices seven years after its takedown
    • Here’s what to know about the upcoming ‘Grand Theft Auto VI’
    Facebook X (Twitter) LinkedIn
    Techie.LKTechie.LK
    Demo
    • Home
    • Local
      1. AI & Machine Learning
      2. Consumer Tech
      3. Cybersecurity
      4. Enterprise Tech
      5. Fintech & Digital Payments
      6. GovTech & e-Governance
      7. Legal & Regulatory Tech
      8. Science & Innovation
      9. Startups & Venture
      10. Telecom & Connectivity
      Featured

      Three Sri Lankan startups selected for Uber Springboard 2026 Programme

      By Techie.lkNovember 20, 20264
      Recent

      Three Sri Lankan startups selected for Uber Springboard 2026 Programme

      November 20, 2026

      Taking Sri Lankan technology to the global stage

      November 20, 2026

      SLT Group strengthens Sri Lanka’s digital transformation

      November 18, 2026
    • International
      • AI & Machine Learning
      • Consumer Tech
      • Cybersecurity
      • Enterprise Tech
      • Fintech & Digital Payments
      • GovTech & e-Governance
      • Legal & Regulatory Tech
      • Science & Innovation
      • Startups & Venture
      • Telecom & Connectivity
    • Interviews
    • Profiles
    • Analysis
    • Contributors
    • Podcasts
    • More
      • About Us
      • Contact Us
    Techie.LKTechie.LK
    Home»International»Vaccine improves survival in people with Acute Myeloid Leukemia (AML)
    International

    Vaccine improves survival in people with Acute Myeloid Leukemia (AML)

    Techie.lkBy Techie.lkNovember 20, 2026Updated:November 20, 2026No Comments4 Views
    Facebook Twitter LinkedIn WhatsApp Reddit Tumblr Email
    Share
    Facebook Twitter LinkedIn

    A new cancer vaccine significantly improved survival in patients with acute myeloid leukemia. Dr. David A. Scheinberg, a leader of immunotherapy drug development at MSK, worked with colleagues to develop this ready-made, “off-the-shelf” vaccine for more than two decades.

    A cancer vaccine appears to significantly improve survival in people in remission from one of the most common and aggressive blood cancers, acute myeloid leukemia (AML), according to new results from a phase 3 clinical trial.

    The vaccine, galinpepimut-S (or GPS), was invented by David A. Scheinberg, MD, PhD, a leader in immunotherapy drug development at Memorial Sloan Kettering Cancer Center (MSK).

    The clinical trial, which included 126 patients, was led by SELLAS Life Sciences Group. The study found:

    • The vaccine reduced the risk of death by 41%.
    • The median overall survival was 24.0 months in those receiving the vaccine, compared with 14.7 months for patients on standard treatments — a difference of 9 months.
    • The vaccine appeared safe, with minimal side effects – most commonly reactions at the injection site.

    As a therapeutic cancer vaccine, it works by teaching the immune system to fight remaining traces of cancer cells that may be undetectable following treatment but ultimately can lead to a relapse.

    The GPS is a complex “peptide” vaccine that triggers a targeted immune response by using synthetic peptides, which are the building blocks of proteins. The vaccine targets a protein called WT1, found in the cancer cells of more than 95% of people with AML (as well as in ovarian cancer, mesothelioma, and other cancers and leukemias).

    The GPS vaccine is ready-made and “off-the-shelf” — as opposed to a personalized vaccine individually designed for each patient. Because off-the-shelf vaccines don’t need to be custom-manufactured, the hope is that they can be mass-produced, stored, and administered right away.

    “Two decades of research have given us a much clearer picture of how the immune system can recognize and attack tumors and leukemias,” Dr. Scheinberg says. “These insights are helping lay the groundwork for these exciting, new immune-based approaches that could safely benefit more people with cancer. These data bring us closer to having the first off-the-shelf vaccine for AML patients.”

    The GPS vaccine: a pressing need for better treatments

    Although rare overall, acute myeloid leukemia is one of the most common types of blood cancer.  It moves quickly and needs aggressive, often harsh, treatment with chemotherapy, sometimes followed by a bone marrow transplant. Even when these therapies stop the cancer, AML often returns, and treatment options have been limited. Modern immunotherapies that have worked well for other cancers have not had success against AML.

    Dr. Scheinberg says cancer vaccines are well-suited to mop up lingering malignant cells after successful treatment. But until recently, results have been disappointing. A major problem was that the vaccines were too narrowly focused or didn’t activate enough parts of the immune system.

    “Tumors have different antigens from cell to cell,” he says. “Some tumor cells are attacked, but others survive and grow. In addition, cancers have several ways of eluding an immune attack, so you need a multipronged response.”

    Back to top

    An innovative design expands the vaccine’s scope

    To create a more comprehensive attack, Dr. Scheinberg designed GPS to use four different peptides derived from the WT1 protein.

    The peptides were slightly altered from their natural form to look more foreign to the immune system. Dr. Scheinberg’s team also added ingredients called “adjuvants” to further boost the immune response.

    When a patient receives an injection, the vaccine is taken in by immune cells called dendritic cells and macrophages. In turn, they stimulate two kinds of T cells, which are the body’s killer immune cells. Once the T cells switch on, they go hunting for cells with high levels of WT1 — a telltale sign of AML.

    It’s a one-two punch that lasts.

    “One of the innovations of this treatment is that it activates two different types of T cells: CD8 T cells and CD4 T cells,” Dr. Scheinberg says. “The CD8 T cells directly attack the cancer cells, while the CD4 T cells help boost the attack and support long-term protection against the cancer. Previous treatments that had been tested did not activate the CD4 T cells, which we realized was critical.”

    SELLAS is preparing to submit the vaccine for approval by the U.S. Food and Drug Administration (FDA) in the first half of 2027.

    Gratifying success after decades of research

    The trial’s results point to the potential of GPS as a completely new form of “maintenance immunotherapy,” which prevents the disease from returning after primary treatment. It also validates the concept that cancer vaccines can be effective if designed and engineered to foil cancer’s tricks to outsmart the immune system.

    Dr. Scheinberg and his colleagues at MSK have been developing GPS for more than two decades. His team persisted in the approach amid skepticism from other scientists and many pharmaceutical companies.

    “I’ve been working in immunology drug development for 40 years, and given the nature of the field, I’ve had plenty of failures and some successes,” he says. “I’m happy this was a success, but I’ll be even happier when I see the first patient be able to get it when they come into the clinic.”

    Dr. Scheinberg says advances in technology, including mRNA-based platforms, promise to speed the development of newer cancer vaccines that use the multipronged approach proved successful by GPS.

    “It’s great for the field, for the young scientists to see that things can actually work,” he says. “I tell the students in my lab, ‘If I could do this, you’ll do it even better because you’ll have better technology.’ ”

    Dr. Scheinberg holds the Vincent Astor Chair.

    Disclosure: Memorial Sloan Kettering (MSK) and Dr. Scheinberg have financial interests related to SELLAS Life Sciences.

    (Memorial Sloan Kettering Cancer Centre)
    Featured
    Share. Facebook Twitter LinkedIn
    Techie.lk
    • Website

    Related Posts

    Kaspersky: Binance and Polymarket hacks

    November 19, 2026

    Kaspersky: “dead” Retadup worm tried to infect at least 15,000 devices seven years after its takedown

    November 19, 2026

    Here’s what to know about the upcoming ‘Grand Theft Auto VI’

    November 18, 2026
    Leave A Reply Cancel Reply

    Demo
    Top Posts

    Chadika Yahampath: Head of Digital Capacity Building, GovTech Sri Lanka

    September 21, 2026308

    The Exit Plan: The Leadership Lessons No Startup Can Afford to Ignore

    August 18, 2026234

    Solve a Global Problem from Sri Lanka: Haridhu Abeygoonaratne on Building a Product Nation

    October 6, 2026137

    The Death of the Traditional Software Engineer: Bridging the Talent Gap in the Post-AI Era

    August 10, 2026117
    Don't Miss
    International

    Vaccine improves survival in people with Acute Myeloid Leukemia (AML)

    By Techie.lkNovember 20, 20264

    A new cancer vaccine significantly improved survival in patients with acute myeloid leukemia. Dr. David…

    Neuroimplants: Autonomy Under Algorithmic Control

    November 20, 2026

    Three Sri Lankan startups selected for Uber Springboard 2026 Programme

    November 20, 2026

    Taking Sri Lankan technology to the global stage

    November 20, 2026
    Stay In Touch
    • Facebook
    • Twitter
    • LinkedIn

    Subscribe to Updates

    Get the latest creative news from SmartMag about art & design.

    Demo
    About Us
    About Us

    Your source for the lifestyle news. This demo is crafted specifically to exhibit the use of the theme as a lifestyle site. Visit our main page for more demos.

    We're accepting new partnerships right now.

    Email Us: techielkeditor@gmail.com
    Contact: +94 77 328 0773

    Facebook X (Twitter) LinkedIn
    Our Picks

    Vaccine improves survival in people with Acute Myeloid Leukemia (AML)

    November 20, 2026

    Neuroimplants: Autonomy Under Algorithmic Control

    November 20, 2026

    Three Sri Lankan startups selected for Uber Springboard 2026 Programme

    November 20, 2026
    Most Popular

    Chadika Yahampath: Head of Digital Capacity Building, GovTech Sri Lanka

    September 21, 2026308

    The Exit Plan: The Leadership Lessons No Startup Can Afford to Ignore

    August 18, 2026234

    Solve a Global Problem from Sri Lanka: Haridhu Abeygoonaratne on Building a Product Nation

    October 6, 2026137
    © 2026 Techie. Designed by NIKO.
    • Terms & Conditions
    • Privacy Policy

    Type above and press Enter to search. Press Esc to cancel.